Trial Profile
Rituximab for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (RAVE) Long-Term Follow-Up Study
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis; Granulomatosis with polyangiitis; Microscopic polyangiitis
- Focus Adverse reactions
- Acronyms RAVELOS
- 17 Oct 2017 Status changed from recruiting to discontinued.
- 25 Aug 2015 New trial record